A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2015
At a glance
- Drugs Dasabuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Abbott Laboratories; AbbVie
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual patient number (35) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.